Immunovant, Inc. SEC filings IMVT
Immunovant, Inc. has 648 filings in SEC EDGAR's recent list, going back to Jan 23, 2019. Its latest annual report, Form ARS, was filed on Jul 22, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 3, 2026 (shareholder vote results). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 22, 2026 | — |
| DEF 14A | Proxy statement | Jul 22, 2026 | Sep 2, 2026 |
| DEFA14A | Additional proxy material | Jul 9, 2025 | — |
| DEF 14A | Proxy statement | Jul 9, 2025 | Aug 27, 2025 |
| DEFA14A | Additional proxy material | Jun 26, 2024 | — |
| DEF 14A | Proxy statement | Jun 26, 2024 | Aug 12, 2024 |
| DEFA14A | Additional proxy material | Jun 26, 2023 | — |
| DEF 14A | Proxy statement | Jun 26, 2023 | Aug 21, 2023 |
| DEFA14A | Additional proxy material | Jun 30, 2022 | — |
| DEF 14A | Proxy statement | Jun 30, 2022 | Mar 31, 2022 |
| DEF 14A | Proxy statement | Aug 12, 2021 | Sep 9, 2021 |
| PRE 14A | Preliminary proxy statement | Aug 2, 2021 | Aug 2, 2021 |
| DEFA14A | Additional proxy material | Jul 9, 2020 | — |
| DEF 14A | Proxy statement | Jul 9, 2020 | Aug 19, 2020 |
| DEFA14A | Additional proxy material | Dec 13, 2019 | — |
| DEFA14A | Additional proxy material | Dec 2, 2019 | — |
| DEFM14A | Filing | Nov 27, 2019 | — |
| DEFA14A | Additional proxy material | Nov 25, 2019 | — |
| DEFA14A | Additional proxy material | Nov 14, 2019 | — |
| DEFA14A | Additional proxy material | Nov 12, 2019 | — |
| DEFA14A | Additional proxy material | Oct 29, 2019 | — |
| DEFA14A | Additional proxy material | Oct 15, 2019 | — |
| DEFA14A | Additional proxy material | Oct 8, 2019 | — |
| DEFA14A | Additional proxy material | Oct 4, 2019 | — |
| PREM14A | Preliminary proxy statement | Oct 2, 2019 | Oct 2, 2019 |
| DEFA14A | Additional proxy material | Oct 2, 2019 | — |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMVT (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1764013
- Former names
- Health Sciences Acquisitions Corp (until Dec 20, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.